Patent intelligence · US
US 11629060
Purification of clinoptilolite
Purification of clinoptilolite
Patent details — US 11629060
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 18, 2023
- Expiration
- Apr 13, 2043
- Applicant
- Revelation Health LLC
- Claims
- 13
- CPC classes
- A61K, A61K33/06, A61K9/127, A61P
Quick answer
US 11629060 (Purification of clinoptilolite) is held by Revelation Health LLC. Status: granted. Granted Apr 18, 2023. Expires Apr 13, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Revelation Health LLC
- Grant date
- Expiration
- Claims
- 13
- CPC classes
- A61K, A61K33/06, A61K9/127, A61P, A61P39/06
More from Revelation Health LLC
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 11629060?
US 11629060 (Purification of clinoptilolite) is held by Revelation Health LLC. Status: granted. Granted Apr 18, 2023. Expires Apr 13, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11629060?
Revelation Health LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 2 pharmaceutical patents for this assignee.
When does US 11629060 expire?
Our index shows an expiration date of Apr 13, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.